A panelist explains how the distinct mechanisms of erythropoiesis-stimulating agents (ESAs), luspatercept, and imetelstat ...

In late 2019, the FDA approved luspatercept -- an erythroid maturation agent administered subcutaneously every 3 weeks -- for the treatment of anemia in adults with thalassemia who require regular ...

Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...

Myelodysplastic Syndrome Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035 The report provides a detailed analysis of the current myelodysplastic ...

If approved, it would compete with Bristol-Myers Squibb’s erythroid maturation agent Reblozyl (luspatercept), which was cleared to treat anaemia in adults with low-risk, relapsed MDS in 2020 and ...

It offers REBLOZYL, an erythroid maturation agent for the treatment of anemia in adult patients with beta-thalassemia and transfusion-dependent anemia.

Cohen, E. and Kubinak, N. (2025) A Rare Presentation of Cavernous Sinus Thrombosis in a Young Female. Surgical Science, 16, 330-338. doi: 10.4236/ss.2025.166034 .

To address this, we systematically analyzed the subcellular location of IDH1 in erythroid cells at different time points on umbilical cord blood-derived CD34 + cells induced to normal human terminal ...

To address this, we systematically analyzed the subcellular location of IDH1 in erythroid cells at different time points on umbilical cord blood-derived CD34 + cells induced to normal human terminal ...

These findings highlight the dual roles of antioxidants in cancer. Their impact depends on cancer type, stage, and genetic ...